 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...3132333435363738394041...266267» |
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, IO biomarker: RESET-R: Immunotherapy in Patients With Early dMMR Rectal Cancer (clinicaltrials.gov) - Aug 14, 2023
P2, N=39, Recruiting, Sponsor: Odense University Hospital
Not yet recruiting --> Recruiting
- ||||| GRANITE / Gritstone bio
Enrollment closed, Combination therapy, Checkpoint inhibition, Checkpoint block, Metastases: GRANITE: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2023
P2/3, N=700, Active, not recruiting, Sponsor: Gritstone bio, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (clinicaltrials.gov) - Aug 14, 2023
P1/2, N=30, Active, not recruiting, Sponsor: Hatim Husain
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion, Checkpoint inhibition: TICIMEL: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (clinicaltrials.gov) - Aug 14, 2023
P1, N=33, Completed, Sponsor: Institut Claudius Regaud
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Journal: Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies. (Pubmed Central) - Aug 14, 2023
In conclusion, the BLA-BLIP sensors provide a rapid biosensor for TDM of trastuzumab and ipilimumab with the potential to improve therapy. The sensitivity of this platform alongside its rapid action would be suitable for bedside monitoring in a point-of-care (PoC) setting.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Exploring the Rising Incidence of Myocarditis and Other Cardiovascular Adverse Events of Nivolumab and Ipilimumab: Analysis of FDA Adverse Event Reporting System Database (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_5081;
Clinicians need to be vigilant in detecting immune-mediated myocarditis, as it often manifests with nonspecific symptoms, with early onset and rapid progression. Given the growing utilization of these medications, it is imperative to conduct additional randomized controlled trials to gain a better understanding of their cardiovascular safety profile.
- Stress Cardiomypoathy in the Patient on Immune Checkpoint Inhibitors; a Pharmacovigilance Study From 2013-2023 FAERS Database (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_3898;
Immune checkpoint inhibitor-induced cardiac ADRs, specifically stress cardiomyopathy, were found to be serious and associated with unfavorable outcomes. Physicians should remain vigilant regarding cardiac symptoms in patients receiving immune checkpoint inhibitors, as early detection can improve overall outcomes.
- Combinatorial Immune Checkpoint Blockade Increases Myocardial Secretion of H-FABP, NT-Pro-BNP, NLRP-3 Inflammasome, Interleukin-1 (Zone 4, Science and Technology Hall, Level 2) - Aug 12, 2023 - Abstract #AHA2023AHA_3896;
Moreover, anti PD-L1blocking agent Atezolizumab is actually under study in association with Ipilimumab as innovative thearpy for metastatic lung cancer... Data of the present study, although in vitro, indicate that combinatorial immune checkpoint blockade, induce a pro- inflammatory phenotype.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Pseudo-Progression of Melanoma Treated with Nivolumab/Ipilimumab: A Case Report. (Pubmed Central) - Aug 11, 2023
Clinicians should consider PET-CT imaging in cases of suspected pseudo-progression to avoid unnecessary changes in therapy. Patient response to immunotherapy demonstrates the effectiveness of immunotherapy in treating advanced melanoma.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Adverse events, Metastases: Editorial Comment from Dr. Kato to Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. (Pubmed Central) - Aug 11, 2023
Patient response to immunotherapy demonstrates the effectiveness of immunotherapy in treating advanced melanoma. No abstract available
- ||| Clinical guideline, Journal: SEOM SOGUG clinical guideline for treatment of kidney cancer (2022). (Pubmed Central) - Aug 9, 2023
In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib...When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical data, Journal: Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 (Pubmed Central) - Aug 8, 2023
While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC. The effectiveness of nivolumab plus ipilimumab was comparable between patients with metastatic RCC aged?<?75 and those???75
- ||| LN-145-S1 / Iovance Biotherap, LN-145 / Iovance Biotherap
Enrollment closed, Enrollment change: NCI-2018-00918: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (clinicaltrials.gov) - Aug 8, 2023
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
The effectiveness of nivolumab plus ipilimumab was comparable between patients with metastatic RCC aged?<?75 and those???75 Recruiting --> Active, not recruiting | N=95 --> 30
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1. (Pubmed Central) - Aug 7, 2023
P3
At 5-year follow-up, nivolumab plus ipilimumab continued to show long-term durable clinical benefit versus chemotherapy, regardless of tumor PD-L1 expression. Consistent with findings for the global population, these data support the use of nivolumab plus ipilimumab as first-line treatment in Japanese patients with metastatic NSCLC.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney. (Pubmed Central) - Aug 7, 2023
Consistent with findings for the global population, these data support the use of nivolumab plus ipilimumab as first-line treatment in Japanese patients with metastatic NSCLC. No abstract available
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis. (Pubmed Central) - Aug 7, 2023
No abstract available We highlighted the instrumental role of CTLA-4 immune checkpoint in GCA, which provides a strong rationale for targeting this pathway.
- HYPERCALCEMIA SECONDARY TO CALCITRIOL PRODUCTION FROM DUAL COMBINATION IMMUNOTHERAPY IN PULMONARY METASTATIC MELANOMA (Convention Center Exhibit Hall - Rapid Area 3C) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4844;
- TRACHEOBRONCHIAL DISSEMINATION OF METASTATIC MELANOMA: A RARE CASE OF ???DARK BRONCHOSCOPY??? (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4026;
- FACTORS ASSOCIATED WITH ONE-YEAR SURVIVAL AMONG PATIENTS WHO DEVELOP IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3702;
- HYPERCAPNIC RESPIRATORY INSUFFICIENCY ASSOCIATED WITH DUAL IMMUNE CHECKPOINT INHIBITORS IN A PATIENT WITH RENAL CELL CARCINOMA (Convention Center Exhibit Hall - Rapid Area 4B) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3473;
- WHEN TWO WORLDS COLLIDE: ARRHYTHMOGENIC CARDIOMYOPATHY FROM METASTATIC MELANOMA (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2845;
- ACUTE RESPIRATORY FAILURE DUE TO IMMUNE CHECKPOINT INHIBITOR-INDUCED MYASTHENIA GRAVIS (Convention Center Exhibit Hall - Rapid Area 1B) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2511;
- A RARE CASE OF PRIMARY MALIGNANT MELANOMA OF LUNG (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2431;
- CHEST PAIN - ACUTE CORONARY SYNDROME OR RENAL CELL CARCINOMA? A RARE SITE OF DISTANT METASTASES (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2337;
- nemvaleukin alfa (ALKS 4230) / Alkermes
A CASE OF PULMONARY TOXICITY ASSOCIATED WITH NEMVALEUKIN ALFA (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2233;
- A RARE CASE OF COMBINATION IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS RAPIDLY DEVELOPING INTO PERICARDIAL TAMPONADE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2157;
- AN EYE TO THE FUTURE: A CASE OF UVEAL MELANOMA METASTASIS CAUSING CENTRAL AIRWAY OCCLUSION (Convention Center Exhibit Hall - Rapid Area 3C) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1777;
- A RARE CASE OF PULMONARY METASTATIC MELANOMA OF UNKNOWN PRIMARY (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1422;
- NOT ALL SYSTEMS ARE A GO: A CASE OF MULTI-SYSTEM CHECKPOINT INHIBITOR TOXICITY (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1147;
- NASAL SEPTUM DEVIATION DUE TO NASAL MELANOMA: A CASE REPORT (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1126;
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
PULMONARY GRANULOMATOUS/SARCOID-MEDIASTINAL LYMPHADENOPATHY IN A PATIENT RECEIVING IPILIMUMAB AND NIVOLUMAB FOR MALIGNANT MUCOSAL MELANOMA (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1043;
- || Opdivo (nivolumab) / BMS, NG-350A / Akamis Bio, Yervoy (ipilimumab) / BMS
Enrollment closed: REVOLUTION: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 4, 2023
P1, N=45, Active, not recruiting, Sponsor: Parker Institute for Cancer Immunotherapy
We highlighted the instrumental role of CTLA-4 immune checkpoint in GCA, which provides a strong rationale for targeting this pathway. Recruiting --> Active, not recruiting
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Real-world evidence, Real-world: It's interesting. I wonder how the COSMIC-313 regimen would fare in poor-risk in the real world setting, with the early improvement with cabo + ipi/nivo. That said, the toxicity in real world practice is likely to be a major issue! (Twitter) - Aug 3, 2023
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial suspension: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Aug 3, 2023
P2, N=146, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Suspended
- || CIML NK - Dana / Farber Cancer Institute
Enrollment change, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Aug 3, 2023
P1, N=25, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Suspended N=12 --> 25
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. Reply. (Pubmed Central) - Aug 2, 2023
N=12 --> 25 No abstract available
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. (Pubmed Central) - Aug 2, 2023
No abstract available No abstract available
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. (Pubmed Central) - Aug 2, 2023
No abstract available No abstract available
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. (Pubmed Central) - Aug 2, 2023
No abstract available No abstract available
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. (Pubmed Central) - Aug 2, 2023
No abstract available No abstract available
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Trial completion date, Metastases: Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Aug 2, 2023
P1, N=34, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
No abstract available Trial completion date: Jul 2023 --> Jul 2025
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Aug 2, 2023
P1, N=120, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Jul 2023 --> Jul 2025 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
Reimbursement, US reimbursement, Journal, HEOR: Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data. (Pubmed Central) - Aug 1, 2023
Our findings suggest that there may be a trade-off between certainty and the ICER. Conducting health technology re-assessments of certain oncology products on the basis of longer-term data availability, especially for those health technology adoption decisions made based on immature clinical data, may be of value to decision makers.
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Metastases: EMPOWER-Lung 3: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (clinicaltrials.gov) - Aug 1, 2023
P3, N=790, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Conducting health technology re-assessments of certain oncology products on the basis of longer-term data availability, especially for those health technology adoption decisions made based on immature clinical data, may be of value to decision makers. Trial completion date: Jul 2023 --> Jan 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial: Naltrexone and Propranolol Combined With Immunotherapy (clinicaltrials.gov) - Aug 1, 2023
P1, N=12, Not yet recruiting, Sponsor: Rutgers, The State University of New Jersey
- | Enrollment open, Adverse events, Checkpoint inhibition: EXIT: EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database (clinicaltrials.gov) - Aug 1, 2023
P=N/A, N=141630, Recruiting, Sponsor: Groupe Hospitalier Pitie-Salpetriere
Trial completion date: Jul 2023 --> Jan 2025 Active, not recruiting --> Recruiting
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal, Checkpoint inhibition, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. (Pubmed Central) - Jul 31, 2023
Cabozantinib in Japanese patients with advanced renal cell carcinoma who failed immune checkpoint inhibitors was efficacious and had a manageable safety profile. These results appear to be similar to those of previous clinical trials.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, IO biomarker: A082101: Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma (clinicaltrials.gov) - Jul 31, 2023
P2, N=26, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
These results appear to be similar to those of previous clinical trials. Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: WITNESS: Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer (clinicaltrials.gov) - Jul 31, 2023
P=N/A, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Yervoy (ipilimumab) / Ono Pharma, BMS
PK/PD data, Preclinical, Journal: Preclinical Pharmacokinetic Study on Caffeine as an Excipient for Monoclonal Antibody Formulations. (Pubmed Central) - Jul 30, 2023
Two preclinical studies were conducted in rats to evaluate pharmacokinetic (PK) parameters of caffeine as well as its effects on the PK profile of a model mAb, namely ipilimumab...In addition, SQ injection of caffeine at different dose levels showed no irritation at the injection site or adverse effects. Results from the current PK studies warrant further development of caffeine as a viscosity reducing excipient for mAb SQ formulations.